Most Recent Publications Search Assessing the immunogenicity risk of salmon calcitonin peptide impurities using in silico and in vitro methods 08-2024 Poster: Immunogenicity Risk Assessment of Salmon Calcitonin Peptide Impurities Using In Silico and In Vitro Methods 05-2024 Poster: Rapid and Predictive Immunogenicity Risk Assessments Using In Silico Methods 05-2024 Poster: Comprehensive assessment of immunogenicity risk of host cell proteins in biologics and vaccines using in silico and in vitro methods 05-2024 Poster: An “I” (Immunogenicity Risk Assessment) for an Eye (Ophthalmology Biologics) 05-2024 Individual and population-level variability in HLA-DR associated immunogenicity risk of biologics used for the treatment of rheumatoid arthritis 05-2024 In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies 04-2024 Neoadjuvant personalized cancer vaccines: the final frontier? 01-2024 A SARS-CoV-2 NSP7 homolog of a Treg epitope suppresses CD4+ and CD8+ T cell memory responses 11-2023 Development of IFNβ-1a versions with reduced immunogenicity and full in vitro biological activity for the treatment of multiple sclerosis 11-2023 Does human homology reduce the potential immunogenicity of non-antibody scaffolds? 10-2023 Poster: iVAX for antigen discovery, vaccine design, diagnostics, and epidemiology 09-2023 « Older Entries
Assessing the immunogenicity risk of salmon calcitonin peptide impurities using in silico and in vitro methods 08-2024
Poster: Immunogenicity Risk Assessment of Salmon Calcitonin Peptide Impurities Using In Silico and In Vitro Methods 05-2024
Poster: Comprehensive assessment of immunogenicity risk of host cell proteins in biologics and vaccines using in silico and in vitro methods 05-2024
Individual and population-level variability in HLA-DR associated immunogenicity risk of biologics used for the treatment of rheumatoid arthritis 05-2024
In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies 04-2024
Development of IFNβ-1a versions with reduced immunogenicity and full in vitro biological activity for the treatment of multiple sclerosis 11-2023